CCR4 and neoplasm: To support the last statement one could take into account that, for example, antagonists of the NFAT family of transcription factors are known to exhibit strong antineoplastic promoting activity (for review see [43]), and anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking anti-tumor immune responses in humans [44].